PGNY — Progyny, Inc.

Summary of Progyny, Inc. Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Q3 revenue exceeded guidance, reaching approximately $307.7 million, reflecting growth of 9% year-over-year (23% when excluding a large former client).
• Profitability: Adjusted EBITDA margin was 17.5%, with gross margin at 23%. Operating cash flow for Q3 was over $50 million, totaling $156 million for the first nine months of 2025.
• New Covered Lives: Progyny added around 900,000 new covered lives, slightly below the target of 1 million but higher than investor expectations.
• Client Retention: Nearly 100% renewal rate for existing clients for 2026, with 30% of clients expanding their benefits.

2. Strategic Updates and Business Highlights

• Product Expansion: Introduction of a supplemental plan for small and mid-sized companies, aimed at providing predictable costs for fertility benefits.
• Global Offering: Launch of Progyny Global, integrating family building and reproductive health services for multinational employers.
• Market Position: Continued leadership in the fertility benefits market, with a diverse client base across multiple industries and strong engagement metrics.

3. Forward Guidance and Outlook

• Q4 Guidance: Expected revenue between $292.7 million to $307.7 million, with adjusted EBITDA projected between $45.3 million to $49.3 million.
• Full Year 2025 Guidance: Revenue projected between $1.263 billion to $1.278 billion (growth of 8.2% to 9.5%), with adjusted EBITDA expected between $216 million to $220 million.
• Utilization Rates: Full-year utilization rates are expected to be slightly lower than 2024, with ART cycles per unique utilizer projected at 0.91 to 0.92.

4. Bad News, Challenges, or Points of Concern

• Pipeline Delays: Some large employers were unable to finalize decisions in time, contributing to a shortfall in new covered lives.
• Economic Headwinds: Ongoing macroeconomic uncertainties and high medical cost inflation may impact future client decisions and overall market conditions.
• Utilization Variability: There is potential for variability in member engagement and treatment rates, which could affect revenue projections.

5. Notable Q&A Insights

• Client Layoffs: Management noted no significant layoffs among clients that would impact utilization, citing that recent layoffs were small and not widespread.
• Drug Pricing Concerns: Management clarified that recent announcements regarding cash pricing for fertility medications would not significantly impact their covered benefits or pricing strategies.
• Upsell Opportunities: The company is focused on ongoing discussions with existing clients to expand services, leveraging new products to enhance relationships and drive additional revenue.
• Sales Strategy: The sales team is adapting to a changing market, emphasizing member experience, quality, and cost control as key areas of focus for employers.

Overall, Progyny reported strong financial performance and strategic advancements while acknowledging potential challenges ahead in a dynamic market environment.